| Enoxaparin is a cost-effective adjunct to fibrinolytic therapy for ST-elevation myocardial infarction in contemporary practice. | |
| | |
MedLine Citation:
|
PMID: 20422473 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
INTRODUCTION: In patients receiving fibrinolytic therapy for ST-elevation myocardial infarction (STEMI), adjunct treatment with enoxaparin has been shown to provide superior net clinical benefit compared with unfractionated heparin (UFH) in the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment - Thrombolysis in Myocardial Infarction (ExTRACT-TIMI) 25 study. The objective of this study was to compare the cost effectiveness of enoxaparin and UFH strategies. METHODS: A cost-utility analysis was conducted using a two-stage model: (1) A 30-day decision tree analytical model for the acute treatment phase, and (2) a lifetime Markov model (from 30 days post-STEMI until death) populated using patient survival data. RESULTS: Assuming treatment continuation for 7 days, the mean day 1-30 incremental cost associated with enoxaparin was pound 49 per patient, and mean lifetime incremental cost was pound 592 per patient ( pound 91,091 vs. pound 90,499, respectively). Given an additional 0.048 life years gained per patient with enoxaparin, the cost per life year saved was pound 12,353, and given an additional 0.038 quality-adjusted life years (QALY) per patient with enoxaparin, the cost per QALY was pound 15,413. In an alternative scenario, reflecting contemporary practice assuming early treatment discontinuation at 48 hours, for example following urgent revascularization, the incremental cost per QALY was pound 13,556. CONCLUSION: The use of an enoxaparin versus UFH strategy in patients receiving fibrinolytic therapy for STEMI, whether continued for 7 days or discontinued early, for example following urgent revascularization, is cost effective at a pound 20,000 willingness-to-pay threshold. |
| | |
Authors:
|
Ian Menown; Gilles Montalescot; Nikhal Pal; Carrie Fidler; Michelle Orme; Samantha Gillard |
Related Documents
:
|
10486693 - Management strategies in unstable coronary artery disease--current problems and future ... 11559263 - Aspirin use and all-cause mortality among patients being evaluated for known or suspect... 15825693 - Acute respiratory distress syndrome after early successful primary percutaneous coronar... |
Publication Detail:
|
Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't Date: 2010-04-23 |
Journal Detail:
|
Title: Advances in therapy Volume: 27 ISSN: 1865-8652 ISO Abbreviation: Adv Ther Publication Date: 2010 Mar |
Date Detail:
|
Created Date: 2010-05-13 Completed Date: 2010-08-17 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8611864 Medline TA: Adv Ther Country: United States |
Other Details:
|
Languages: eng Pagination: 181-91 Citation Subset: T |
Affiliation:
|
Craigavon Cardiac Centre, Craigavon, Northern Ireland, UK. ian.menown@southerntrust.hscni.net |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Cost-Benefit Analysis Decision Trees Electrocardiography Enoxaparin / economics*, therapeutic use Fibrinolytic Agents / economics*, therapeutic use Heparin / economics*, therapeutic use Humans Markov Chains Myocardial Infarction / drug therapy* Quality-Adjusted Life Years |
| Chemical | |
Reg. No./Substance:
|
0/Enoxaparin; 0/Fibrinolytic Agents; 9005-49-6/Heparin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Treatment of primary immunodeficiency with Kiovig(R): a literature review.
Next Document: The cost of our aging population.